stockrow
Friday 6 November 2026
Export ANIP’s income statement to Excel — free account
ANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024.
- Revenue
- +27.6%
- EPS
- +29.4%
- Free cash flow
- +85.5%
- Total debt
- −96.2%
Quarter to September 2026, against a year earlier
67.14
2.48
−3.56%
Follow ANIP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
22.55 | 18.71 | 17.14 | 14.03 |
P/S ratio |
1.79 | 1.74 | 1.79 | 1.48 | |
P/FCF ratio |
10.49 | 8.80 | 10.46 | 7.71 | |
P/Operating CF |
52.13 | 27.55 | 30.91 | 18.39 | |
P/B ratio |
2.93 | 2.86 | 2.93 | 2.42 | |
Price to Tangible BV |
0.00 | 49.24 | 20.64 | 10.89 | |
EV/Sales |
2.16 | 2.05 | 2.03 | 1.65 | |
EV/EBITDA |
9.41 | 8.89 | 8.41 | 7.27 | |
EV/Operating CF |
10.29 | 9.09 | 10.48 | 7.49 | |
EV/FCF |
12.63 | 10.37 | 11.86 | 8.59 | |
Quick Ratio |
2.07 | 2.43 | 2.29 | 2.25 | |
Current Ratio |
2.71 | 3.12 | 2.91 | 2.75 | |
Net Debt/EBITDA |
5.62 | 4.81 | 3.90 | 0.00 | |
Debt/Assets |
42.84% | 43.16% | 40.86% | 1.49% | |
Debt/Equity |
1.14 | 1.09 | 1.02 | 0.04 | |
Asset Turnover |
0.65 | 0.68 | 0.69 | 0.70 | |
Operating CF/Net income |
1.10 | 1.98 | 2.29 | 2.38 | |
Capex/Depreciation |
(0.06) | (0.54) | (0.16) | 0.00 | |
Interest Coverage |
7.88 | 10.32 | 11.13 | 17.14 | |
Research and Development Expense of Revenue |
4.96% | 4.46% | 5.54% | 4.47% | |
Selling, General and Administrative Expense of Revenue |
33.51% | 31.02% | 34.45% | 32.62% | |
Intangible Assets out of Total Assets |
0.38 | 0.37 | 0.34 | 0.32 | |
Share Based Compensation of Revenue |
3.95% | 4.29% | 4.29% | 4.00% | |
Graham Net Nets |
(0.09) | (0.07) | (0.04) | (0.02) | |
Graham Number |
46.08 | 49.86 | 55.39 | 59.17 | |
Earnings Yield |
4.43% | 5.34% | 5.83% | 7.13% | |
Free Cash Flow Yield |
9.53% | 11.37% | 9.56% | 12.97% | |
Revenue per Share |
12.32 | 11.35 | 12.57 | 13.71 | |
Operating CF per Share |
1.51 | 2.79 | 2.68 | 3.95 | |
Capex per Share |
(0.07) | (0.54) | (0.14) | (0.64) | |
Free Cash Flow per Share |
1.44 | 2.25 | 2.53 | 3.31 | |
Cash per Share |
14.70 | 15.59 | 17.77 | 20.57 | |
Shareholders Equity per Share |
26.96 | 26.89 | 28.23 | 30.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
26.96 | 26.89 | 28.23 | 30.04 | |
Free Cash Flow |
28.96 | 47.05 | 53.62 | 70.28 | |
Working Capital |
475.01 | 507.57 | 541.78 | 574.10 | |
Capital Expenditures |
(1.40) | (11.32) | (3.05) | (13.50) | |
Net Current Asset Value |
(146.54) | (112.59) | (71.47) | (27.73) | |
EV/EBIT |
17.15 | 15.32 | 13.21 | 10.31 | |
Capex to Sales |
0.01 | 0.05 | 0.01 | 0.05 | |
Price to Operating Income |
14.25 | 12.99 | 11.65 | 9.26 | |
| Other line items | |||||
Average Receivables |
251.40 | 237.88 | 250.06 | 278.53 | |
Average Payables |
54.12 | 61.38 | 64.20 | 72.11 | |
Average Inventory |
139.92 | 140.44 | 140.73 | 141.44 | |
Average Assets |
1,362.42 | 1,357.20 | 1,418.56 | 1,487.91 | |
Average Common Equity |
472.20 | 490.46 | 516.98 | 571.47 |
Columns are period end dates · fundamentals updated 5 Nov 2026